RESEARCH DIGEST // MITOCHONDRIAL-DERIVED PEPTIDE
MOTS-c peptide is a 16-amino-acid signal decoded from mitochondrial DNA and studied in metabolism and aging research.
What the published literature measured — the AMPK mechanism, the aged-mouse performance data, the human biomarker thread — with every quantitative claim cited and every gap labeled.
The short version
The MOTS-c peptide is a tiny molecule your own cells make. It is encoded not in the main genome but inside the DNA of the mitochondria — the cell's power plants — and it acts as a chemical message about energy. In mice, giving extra MOTS-c improved blood-sugar handling, blocked diet-driven weight gain, and made even old animals run further on a treadmill. In people, the molecule itself rises with exercise and shifts with age, but no completed human trial has tested injecting it. Everything precise on this page comes from published studies; every place the human evidence stops, we say so.
What the MOTS-c literature has established
MOTS-c was identified in 2015 as a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1 [1]. It is one of a small family of mitochondrial-derived peptides — short proteins written into mitochondrial DNA rather than the cell nucleus.
Its core action is metabolic. MOTS-c inhibits the folate cycle (the set of reactions a cell uses to build the parts of DNA and to pass around one-carbon chemical tags), which causes the intermediate AICAR to accumulate and activates AMPK — the enzyme a cell uses as its low-fuel sensor [1]. In mice, that pathway translated into measurable outcomes: MOTS-c treatment prevented diet-induced obesity and the insulin resistance that comes with a high-fat diet, with skeletal muscle as the primary target organ [1].
The story is not only metabolic. Exercise raises the body's own MOTS-c, and giving extra MOTS-c improved physical performance in young, middle-aged, and old mice — a result that earned the peptide its description as a candidate exercise mimetic (a molecule that copies some of the molecular changes of physical training) [2]. A separate study showed MOTS-c does something rare for a mitochondrial peptide: under stress it leaves the mitochondria and enters the nucleus to switch genes on and off [3].
The honest counterweight is the human evidence. There are no completed interventional human trials of injected MOTS-c [4]. The human data are observational: the molecule rises with exercise, falls in obese children, and, in one dialysis cohort, tracked with mortality risk [12]. That gap between consumer interest and clinical proof is exactly what this digest exists to map.
What Is MOTS-c?
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded inside the mitochondrial genome, in the MT-RNR1 (12S rRNA) region [1]. Molecular weight is 2174.61 Da; CAS 1627580-64-6; sequence MRWQEMGYIFYPRKLR. It is highly conserved across mammals and is detectable in human plasma and skeletal muscle, where levels are exercise-inducible and change with age [4].
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that inhibits the folate cycle to activate AMPK and, under stress, translocates to the nucleus to regulate gene expression [1][3]. Its best-characterized effects are on glucose handling and skeletal muscle in animal models; a 2024 study identified casein kinase 2 (CK2) — a constantly-active enzyme that tags other proteins — as a direct binding target [5]. Human evidence remains observational rather than interventional [4].
How this site reads the evidence
This is a literature digest, not a clinic and not a vendor. Three reading rules run through every page.
First, species are labeled. A result in mice is reported as a result in mice. The 0.5-15 mg/kg/day figures throughout the research are rodent intraperitoneal doses [1][2] — animal methodology, never a human instruction. See how MOTS-c doses are expressed for the full framing.
Second, the human thread is kept separate and honest. The strongest human signals are biomarker associations: serum MOTS-c is decreased in obese children [11], and in a dialysis cohort it was independently associated with mortality and cardiovascular events [12]. These are associations, not proof that taking MOTS-c changes outcomes. The aging-and-biomarker work is collected on MOTS-c and mitochondrial aging.
Third, the regulatory line is stated plainly. MOTS-c is not an FDA-approved drug and is sold only for laboratory research [4]. The detail — including the FDA 503A compounding framework and where MOTS-c currently sits — is on MOTS-c legal status.